Soltany Setareh, Hemmati Hamid Reza, Toussy Jafar Alavy, Salehi Dina, Toosi Parisa Alavi
Cancer Research Center, Kowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran.
Department of Surgery, Kowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran.
J Family Med Prim Care. 2020 Mar 26;9(3):1562-1566. doi: 10.4103/jfmpc.jfmpc_944_19. eCollection 2020 Mar.
One of the most frequent distressing diseases which causes anal pain and bleeding after defecation is anal fissure. Despite a poorly understood pathogenesis, the internal anal sphincter spasm has been identified to play a central role in pathogenesis. Recently, botulinum toxin is being used increasingly for the treatment of chronic anal fissure to achieve chemical sphincterotomy and reduce internal sphincter tonicity. Based on the heterogeneity among the published studies, we aimed this study to evaluate its healing rate and for recognizing the factors of patients which may affect the outcome.
In a prospective case series medical research, 106 patients who suffer from chronic anal fissure were treated by botulinum toxin injections. All patients received 30 units of botulinum toxin and were physically examined every week for 2 months. They were evaluated for bleeding, pain, hematoma, thrombosis, infection, incontinence, and healing of the fissure. At the end of the follow-up period, the fissure healing rate and its relation to age, gender, prior topical therapy, duration of symptoms, and the position of the fissure were assessed.
At the end of the study (8 weeks), the healing rate was 84.9% (90 patients responded to injections). Healing rate was higher in females and in patients who experienced a shorter duration of symptoms before injection. The mean healing time was 4.68 weeks. In addition, patients with one fissure (anterior or posterior) demonstrated higher healing rate and shorter healing time compared to patients with two fissures (anterior and posterior).
This study demonstrated that botulinum toxin injection is safe and effective for the treatment of chronic anal fissures, with a low complication rate. In addition, the healing rate was higher in females, patients with shorter duration of symptoms, and those with one fissure.
肛裂是排便后引起肛门疼痛和出血的最常见的令人痛苦的疾病之一。尽管其发病机制尚不清楚,但已确定肛门内括约肌痉挛在发病机制中起核心作用。最近,肉毒杆菌毒素越来越多地用于治疗慢性肛裂,以实现化学性括约肌切开术并降低内括约肌张力。基于已发表研究之间的异质性,我们开展本研究以评估其治愈率,并识别可能影响治疗结果的患者因素。
在一项前瞻性病例系列医学研究中,106例慢性肛裂患者接受了肉毒杆菌毒素注射治疗。所有患者均接受30单位肉毒杆菌毒素治疗,并在2个月内每周进行体格检查。对他们进行出血、疼痛、血肿、血栓形成、感染、失禁和肛裂愈合情况的评估。在随访期结束时,评估肛裂愈合率及其与年龄、性别、先前的局部治疗、症状持续时间和肛裂位置的关系。
在研究结束时(8周),治愈率为84.9%(90例患者对注射有反应)。女性和注射前症状持续时间较短的患者治愈率较高。平均愈合时间为4.68周。此外,与有两处肛裂(前后位)的患者相比,仅有一处肛裂(前位或后位)的患者治愈率更高,愈合时间更短。
本研究表明,肉毒杆菌毒素注射治疗慢性肛裂安全有效,并发症发生率低。此外,女性、症状持续时间较短的患者以及仅有一处肛裂的患者治愈率较高。